MYCN and neuroblastoma: Whether quantifying the MYCN amplicon breakpoint outperforms quantifying MYCN copy number in ctDNA, as now performed using a single standardized ddPCR assay (6) within the SIOPEN HR-NBL2 trial (NCT04221035) and the upcoming SIOPEN pragmatic clinical trial (MONALISA) to monitor neuroblastoma relapse with liquid biopsy–sensitive analysis for patients with MYCN-driven tumors, remains to be assessed in comparative studies.